HLA
SGMT icon

Hamilton Lane Advisors’s Sagimet Biosciences SGMT Stock Holding History

Hamilton Lane Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,095
Closed -$65.7K – 25
2025
Q4 		$65.7K Buy
+11,095
New +$79.7K 0.04% 25

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hamilton Lane Advisors's SGMT Position: Q1 2026 in Review

Hamilton Lane Advisors sold out of Sagimet Biosciences (SGMT) in Q1 2026, closing a stake of 11,095 shares — an estimated $65.7K sold.

Hamilton Lane Advisors first reported a position in SGMT in Q4 2025 and held it in 1 quarter. The position peaked at $65.7K in Q4 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Hamilton Lane Advisors reported no remaining Sagimet Biosciences position as of Q1 2026 after selling out during the quarter.
  • Hamilton Lane Advisors sold 11,095 Sagimet Biosciences shares in Q1 2026, an estimated $65.7K.
  • Hamilton Lane Advisors first reported a position in Sagimet Biosciences in Q4 2025 and held it in 1 quarter.
  • Hamilton Lane Advisors's Sagimet Biosciences position peaked at $65.7K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Hamilton Lane Advisors's 13F filing for Q1 2026, filed 8 Apr 2026.